Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sassan Hassassian

Interventional Pain Medicine Manassas, VA Medical Doctor

NPI 1093719536 CMS profile 321177

8644 Sudley Rd, Ste 117, Manassas, VA 20110

Open in the dashboard

General payments

$23,663

457 records reported · program years 2019–2025

Research payments

$1,025

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sassan Hassassian of Manassas, VA is reported in the CMS Open Payments database as having received $23,663 across 457 general payments and $1,025 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $994 29
2024 General $1,260 34
2023 General $1,098 40
2022 General $1,789 60
2021 General $3,307 92
2021 Research $1,025 1
2020 General $3,161 63
2019 General $12,054 139

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sassan Hassassian
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Sassan Hassassian were reported at $994. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Sassan Hassassian Interventional Pain Medicine median Middle half National median
2019 $12,054 $684 $216–$2,079 $163
2020 $3,161 $382 $122–$1,109 $114
2021 $3,307 $552 $167–$1,554 $132
2022 $1,789 $605 $187–$1,924 $149
2023 $1,098 $671 $195–$1,915 $160
2024 $1,260 $684 $206–$1,837 $164
2025 $994 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $16,238 144 payments
  2. Medtronic, Inc. $1,406 22 payments
  3. Collegium Pharmaceutical, Inc. $1,101 79 payments
  4. Scilex Pharmaceuticals Inc. $547 27 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $483 36 payments
  6. Vertos Medical, Inc. $323 2 payments
  7. Boston Scientific Corporation $317 11 payments
  8. AbbVie, Inc. $284 12 payments
  9. SI-BONE, Inc. $251 5 payments
  10. Biodelivery Sciences International, Inc. $214 16 payments
  11. Other $2,500 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,878 430 payments
  2. Consulting Fee $6,340 9 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,853 4 payments
  4. Travel and Lodging $1,542 12 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $1,050 2 payments
Products named General payments · program years 2019–2025
  1. Proclaim Family of SCS IPGs $6,319 52 payments
  2. Neuromodulation Dspsbls and Accs $3,710 8 payments
  3. Prodigy Family of SCS IPGs $2,394 4 payments
  4. INTELLIS ADAPTIVESTIM $1,063 12 payments
  5. XTAMPZA $985 73 payments
  6. IonicRF Generator $700 1 payment
  7. RELISTOR Gastroenterology $468 35 payments
  8. RELISTOR Gastroenterology $435 34 payments
  9. PROCLAIM $426 16 payments
  10. ZTLido $380 17 payments
  11. Other $8,239 302 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $1,025 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

692

Median for Interventional Pain Management: 1,220

Drug cost

$10,258

Median for Interventional Pain Management: $39,344

Branded share of claims

33.7%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 22 $4,414
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 81 $1,376
Gabapentin Generic 190 $978
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 70 $766
Tramadol Hcl-Acetaminophen Tramadol Hcl/Acetaminophen Brand 68 $596
Celecoxib Generic 27 $453
Methocarbamol Generic 73 $441
Morphine Sulfate Er Morphine Sulfate Brand 14 $375
Pregabalin Generic 38 $320
Tramadol Hcl Generic 60 $238

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$264,500

Of which drugs: $38,996

Medicare patients

299

Average age 74

Services billed

6,914

201 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 32%
Ischemic heart disease 29%
Depression 28%
Chronic kidney disease 25%
COPD 19%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg J7322 Office 19 1,776 $23,981
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 73 127 $641

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
  • Collegium Pharmaceutical, Inc. $78
$78 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $60
$60 — —
HORIZANT
  • CutisPharma, Inc. $41
$41 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $39
$39 — —
KRISTALOSE
  • Cumberland Pharmaceuticals, Inc. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

458 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record